Mitoquidone

CAS No. 91753-07-0

Mitoquidone( —— )

Catalog No. M36195 CAS No. 91753-07-0

Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 132 Get Quote
5MG 200 Get Quote
10MG 295 Get Quote
25MG 539 Get Quote
50MG 745 Get Quote
100MG 1008 Get Quote
500MG 2025 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Mitoquidone
  • Note
    Research use only, not for human use.
  • Brief Description
    Mitoquidone, a novel pentacyclic pyrroloquinone, is a potential anticancer agent. Mitoquidone showed good activity in a range of experimental solid tumour models and did not exhibit significant cytotoxicity.
  • Description
    Mitoquidone (GR-30921), a pentacyclic pyrroloquinone, is a potent anticancer agent.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    91753-07-0
  • Formula Weight
    299.32
  • Molecular Formula
    C20H13NO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C2=C3N(C=C2C(=O)C=4C1=CC=CC4)CC=5C(C3)=CC=CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. P A Speth, et al. Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol. 1988;21(4):343-6. ?
molnova catalog
related products
  • Angelicain

    Angelicain is a constituent of Cimicifuga foetida with anti-inflammatory activity.

  • Denudatine

    Denudatine has effects on action potential of ventricular fibers and has inhibition on arrhythmogenic action of aconitine.

  • Isoviolanthin

    Isoviolanthin reduces the migratory and invasive capacities of TGF-β1-treated HCC cells but exhibits no cytotoxic effects on normal live cells, and has potential as a therapeutic agent for the treatment of advanced-stage metastatic HCC.